



HAL
open science

Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells

Guido Bocci, Anna Fioravanti, Concettina La Motta, Paola Orlandi, Bastianina Canu, Teresa Di Desidero, Laura Mugnaini, Stefania Sartini, Sandro Cosconati, Rita Frati, et al.

► To cite this version:

Guido Bocci, Anna Fioravanti, Concettina La Motta, Paola Orlandi, Bastianina Canu, et al.. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. *Biochemical Pharmacology*, 2011, 10.1016/j.bcp.2011.03.022 . hal-00693835

HAL Id: hal-00693835

<https://hal.science/hal-00693835>

Submitted on 3 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells

Authors: Guido Bocci, Anna Fioravanti, Concettina La Motta, Paola Orlandi, Bastianina Canu, Teresa Di Desidero, Laura Mugnaini, Stefania Sartini, Sandro Cosconati, Rita Frati, Alessandro Antonelli, Piero Berti, Paolo Miccoli, Federico Da Settimo, Romano Danesi



PII: S0006-2952(11)00209-7
DOI: doi:10.1016/j.bcp.2011.03.022
Reference: BCP 10862

To appear in: *BCP*

Received date: 2-2-2011
Revised date: 22-3-2011
Accepted date: 25-3-2011

Please cite this article as: Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, Antonelli A, Berti P, Miccoli P, Da Settimo F, Danesi R, Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2011.03.022

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3
4 **Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor,**
5
6 **alone and in combination with SN-38 on endothelial and cancer cells**
7
8
9

10
11 Guido Bocci^{a*}, Anna Fioravanti^a, Concettina La Motta^b, Paola Orlandi^a, Bastianina Canu^a, Teresa Di
12
13 Desidero^a, Laura Mugnaini^b, Stefania Sartini^b, Sandro Cosconati^c, Rita Frati^a, Alessandro Antonelli^d,
14
15 Piero Berti^e, Paolo Miccoli^e, Federico Da Settimo^b, Romano Danesi^a
16
17
18
19
20

21
22 ^aDivision of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy;

23
24 ^bDepartment of Pharmaceutical Sciences, University of Pisa, Pisa, Italy; ^cDepartment of
25
26 Pharmaceutical Chemistry and Toxicology, University of Napoli "Federico II", Napoli, Italy,
27
28

29 ^dMetabolism Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy; ^eDepartment of
30
31 Surgery, University of Pisa, Pisa, Italy
32
33
34
35
36

37 **Running Title**

38
39
40 Antiangiogenic and antitumor activity of CLM3
41

42 **Key words**

43
44
45 CLM3; irinotecan; angiogenesis; synergism; tyrosine kinase inhibitor
46
47

48 ***Author for correspondence**

49
50 Guido Bocci, MD, PhD
51 Division of Pharmacology
52 Department of Internal Medicine
53 University of Pisa
54 Via Roma, 55
55 I-56126 Pisa, Italy
56
57 Phone: +39-050-2218750
58
59 Fax: +39-050-2218758
60
61 e-mail: guido.bocci@med.unipi.it
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Aims. To demonstrate the antiproliferative and pro-apoptotic activity of the novel pyrazolopyrimidine derivative multiple tyrosine kinase inhibitor CLM3, alone and in combination with SN-38 (the active metabolite of irinotecan), on endothelial and tumour cells and to show its mechanism of action.

Methods. Proliferation and apoptotic assays were performed on microvascular endothelial (HMVEC-d) and lung (A549) and thyroid cancer (8305C, TT) cell lines exposed to CLM3 and to the simultaneous combination with SN38 for 72h. Cell-based phospho-VEGFR-2, phospho-EGFR and phospho-RET inhibition assays were performed and ERK1/2 and Akt phosphorylation were quantified by ELISA kits. Cyclin D1 gene expression was performed with real-time PCR and cyclin D1 intracellular concentrations were measured by ELISA.

Results. A strong effect on antiproliferative and pro-apoptotic activity was found with the CLM3 on endothelial and cancer cells, synergistically enhanced by SN38. Phospho-VEGFR-2, phospho-EGFR and phospho-RET levels significantly decreased after CLM3 treatments in activated endothelial and cancer cells; ERK1/2 and Akt phosphorylation were significantly inhibited by lower concentrations of the pyrazolopyrimidine drug in endothelial cells if compared to cancer cells. Moreover, CLM3 treatment greatly inhibited the expression of the *cyclin D1* gene in endothelial and cancer cells, decreasing the cyclin D1 protein intracellular concentration.

Conclusions. The pyrazolopyrimidine derivative CLM3 demonstrated a highly significant and promising antiproliferative and proapoptotic activity, alone and in combination with SN-38, for activated endothelial and cancer cell cells. These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signalling pathways.

1. Introduction

Tyrosine kinase inhibitors (TKIs) have significantly changed the perspectives of current cancer therapy. Understanding the mechanisms of normal and aberrant tyrosine kinase signalling and strategies to inhibit them in angiogenesis and cancer, further promote the development of novel agents [1, 2].

Vascular endothelial growth factors (VEGFs) and their respective family of receptor tyrosine kinases (VEGFRs) are key proteins modulating normal and pathological angiogenesis. Among VEGF receptors, VEGFR-2 is expressed in proliferating vascular endothelial cells of tumours as well as on circulating endothelial progenitor cells, and is related to multiple biological activities of VEGF, such as cell proliferation, migration and survival [3, 4]. The EGFR is required for normal cellular proliferation, survival, adhesion, migration, and differentiation but a dysregulation of this pathway can lead to oncogenesis. Secretory loops may become established when the EGFR receptor is overexpressed and ligands are overproduced by either the tumor or the supporting stroma. EGFR signaling plays a key role in promoting the growth and survival of various types of solid tumors, including non-small cell lung cancer (NSCLC) and breast, gastric, prostate, thyroid and colorectal cancer [5]. The role of the *RET* oncogene in the development of medullary thyroid cancer (MTC) has been well described. RET signaling leads to activation of the RAS/mitogen-activated protein kinase and the phosphatidylinositol 3'kinase/Akt pathways, having a key role in cell growth, differentiation, and survival. The activation of *RET* germline and somatic mutations has been identified as the primary cause of hereditary and sporadic MTC cases [6]. All of these examples illustrate that patients with cancer can significantly profit from the development of tyrosine kinase inhibitors, especially when an activated oncogene is proven to be the underlying cause for a given malignancy.

Based on these considerations, tyrosine kinases of growth factor receptors, such as EGFR and VEGFR-2, are highly attractive targets for the development of new specific anticancer agents [1]. Important preclinical evidence points out numerous cross talks between activated EGFR and VEGFR pathways in tumor biology and both pathways in tumor are upregulated due to the genetic profile, hypoxia and stress induced by anticancer strategies [7]. Therefore, the combination of inhibitors of both pathways is logical and may be more effective than blocking one or the other. This has been successfully investigated using agents with dual inhibition of both EGFR and VEGFR (e.g. ZD6474,

1
2
3
4 BMS-690514 and AEE788) *in vitro* and *in vivo* preclinical settings of tumor angiogenesis [8-10].
5
6 Moreover, recent phase II/III clinical trials have confirmed an important clinical activity of ZD6474 in
7
8 both NSCLC [8, 11] and on RET-mutated MTC [12, 13]. However, all these new small molecules
9
10 demonstrated a higher activity when administered in combinations with chemotherapeutic drugs [14,
11
12 15].

13
14 Researches aimed at the discovery of therapeutically useful inhibitors of TKIs have resulted in
15
16 the identification of a variety of templates which, depending on the nature of attached substituents,
17
18 provide selective inhibition both within and across different families of TKs. One of these privileged
19
20 scaffold is the pyrazolo[3,4-*d*]pyrimidine nucleus, which proved to be a useful core for a variety of
21
22 ATP-competitive TK inhibitors. Compounds belonging to this structural chemotype have been
23
24 described as potent inhibitors of either cytoplasmatic TKs, such as cSrc and Abl [16-21] or receptor
25
26 TKs, in particular EGFR [22].

27
28 The aim of the present study was to test the novel pyrazolopyrimidine derivative multitarget
29
30 ATP-competitive tyrosine kinase inhibitor CLM3 on endothelial and tumour cells for future preclinical
31
32 studies on tumor angiogenesis and NSLC and thyroid carcinoma models.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Materials and methods

2.1 Chemical synthesis of CLM3

All the chemicals listed in this section were purchased from Sigma Chemical Co. (St. Louis, MO, USA). CLM3, (R)-1-phenethyl-N-(1-phenylethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine (**figure 1**), was synthesized following a previously reported procedures [23]. Briefly, the commercially available 3-amino-4-pyrazolecarbonitrile was alkylated with 2-bromoethylbenzene, in dimethylformamide and in the presence of K₂CO₃, to the corresponding 5-amino-1-phenethyl-1*H*-pyrazole-4-carbonitrile. Reaction with boiling formic acid provided the key intermediate 1-phenethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4(5*H*)-one. Treatment with phosphoryl trichloride gave the 4-chloro derivative, which led to the target inhibitor CLM3 by reaction with (R)-(+)-1-phenylethylamine in the presence of triethylamine.

2.2 *In vitro* studies

2.2.1 Materials, drugs and cell lines

Recombinant human epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were from PeproTechEC LTD (London, UK). Cell culture media MCDB131 and RPMI were purchased from Gibco BRL (Paisley, UK), quantitative real-time PCR reagents were from Applied Biosystems (Foster City, CA, USA), supplements and all other chemicals not listed in this section were obtained from Sigma Chemical Co. SN-38 (Pfizer, Groton, CT, USA), the active metabolite of irinotecan, and CLM3 were dissolved in a stock solution of 10 mM in 100% DMSO for *in vitro* studies. The DMSO concentration in control's media was the one used to dilute the highest concentration of CLM3 or SN-38 in the same experiment.

Human dermal microvascular endothelial cells (HMVEC-d; Clonetics, San Diego, CA, USA) were maintained in MCDB131 culture medium supplemented with 10% heat-inactivated FBS, L-glutamine 2 mM, heparin 10 units/ml, EGF 10 ng/ml and bFGF 5 ng/ml. The human undifferentiated thyroid cancer (with papillary component) cell line 8305C (DSMZ, Germany) and the human medullary thyroid cancer cell line TT (ATCC, Manassas, VA, USA) were maintained in 15% FBS RPMI medium

1
2
3
4 supplemented with L-glutamine 2 mM. The human lung carcinoma A549 cells (ATCC, Manassas, VA,
5 USA) were maintained in RPMI culture medium supplemented with 10% FBS, L-glutamine 2 mM.
6
7
8

9 10 **2.2.2. Antiproliferative and apoptosis assay**

11 *In vitro* chemosensitivity was tested on HMVEC-d, A549, 8305C and TT cell lines. Cells were
12 plated in 24-well sterile plastic plates (1% gelatin-coated for the endothelial cells) and treated for 24
13 and 72 h (1×10^3 and 0.5×10^3 cells/well of endothelial or cancer cells, respectively, in 1 ml of medium)
14 with CLM3 (0.001-100 μ M) or with its vehicle alone. At the end of the experiment, cells were
15 harvested with trypsin/EDTA and viable cells counted with a hemocytometer. Cell viability was
16 assessed by trypan blue dye exclusion. The data are presented as the percentage of the vehicle-
17 treated cells. The concentration of drug that reduced cell proliferation by 50% (IC₅₀) vs. controls were
18 calculated by nonlinear regression fit of the mean values of the data obtained in triplicate
19 experiments (at least 9 wells for each concentration).
20
21
22
23
24
25
26
27
28

29 In order to quantify the degree of apoptosis induced by the drug treatments, HMVEC-d, A549
30 and 8305C cells were treated for 24 h and 72 h with CLM3 at three different concentrations: at a
31 concentration corresponding to the experimental IC₅₀ of cell proliferation, at higher and lower
32 concentrations, and with vehicle alone. At the end of the incubation, cells were collected and the Cell
33 Death Detection enzyme-linked immunosorbent assay (ELISA) Plus kit (Roche, Switzerland) were used.
34 All experiments were repeated three time with a least three replicates per sample.
35
36
37
38
39
40
41
42

43 **2.2.3 *In vitro* assessment of synergism between CLM3 and SN-38 on endothelial and tumor cells**

44 The combination of CLM3 with SN-38 was explored on HMVEC-d and 8305C tumor cells with
45 the simultaneous treatment schedule at a fixed molar concentration ratio of 1:1, as follows:
46 simultaneous exposure of CLM3 (0.01-100 μ M) plus SN-38 (0.01-100 μ M) for 72 h. To evaluate the
47 level of interaction (synergistic, additive or antagonist) between CLM3 and SN-38 the Combination
48 Index (CI) method was followed [24]. Briefly, synergism or antagonism for CLM3 plus SN-38 was
49 calculated on the basis of a multiple drug-effect equation, and quantitated by the CI where CI<1, CI=1,
50 and CI>1 indicates synergism, additive effect, and antagonism, respectively. Based on the classic
51 isobologram for mutually exclusive effects, the CI value was calculated as:
52
53
54
55
56
57
58
59

$$60 \text{ CI} = [(D)_1 / (D_x)_1] + [(D)_2 / (D_x)_2]$$

61
62
63
64
65

1
2
3
4 As an example, at the 50% inhibition level, $(D_x)_1$ and $(D_x)_2$ are the concentrations of CLM3 and
5 SN-38, respectively that induce a 50% inhibition of cell growth; $(D)_1$ and $(D)_2$ are the concentrations of
6 CLM3 and SN-38 in combination that also inhibits cell growth by 50% (isoeffective as compared with
7 the single drugs alone). The dose-reduction index (DRI) defined the degree of dose reduction that is
8 possible in a combination for a given degree of effect as compared with the concentration of each
9 drug alone:

$$(DRI)_1 = (D_x)_1 / (D)_1 \text{ and } (DRI)_2 = (D_x)_2 / (D)_2$$

10
11
12
13
14
15
16
17
18
19 The CI and DRI indexes were calculated with the CalcuSyn v.2.0 software (Biosoft, Cambridge,
20 UK).

2.2.4 Cell-based phospho-VEGFR-2, phospho-EGFR and phospho-RET inhibition assay

25
26
27 HMVEC-d (10^5 cells/well), A549 and 8305C cells (5×10^4 cells/well) were seeded and maintained with
28 1% FBS medium. After 24 h, cells were treated continuously for 72 h with CLM3 at a concentration
29 around the experimental IC_{50} of cell proliferation and at a higher and lower concentrations or with
30 vehicle alone. The media were supplemented with rhVEGF 10ng/ml or rhEGF 10ng/ml, depending on
31 the assay to be performed. At the end of the experiment, the medium was removed and cells were
32 rinsed with ice-cold PBS and directly lysed with 0.5 ml ice-cold 1X lysis buffer (20 mM Tris pH7.5, 150
33 mM, 1 mM EDTA, 1 mM EGTA, 1% triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β -
34 glycerolphosphate, 1mM Na_3VO_4 , 1 μ g/ml leupetin; Cell Signaling Technology®, MA, USA, cat.#9803)
35 and 1 mM PMSF to each plate for 5 min at 4°C. Lysates were collected and sonicated on ice for 10 s.
36 The samples were microcentrifuged for 10 min at 4°C and the supernatant was collected. Endothelial
37 cell lysates were assayed as *per* manufacture's instruction with PathScan® phospho-VEGFR-2 (Tyr1175)
38 and Total VEGFR-2 sandwich ELISA kits (Cell Signaling Technology®) and with PathScan® phospho-EGFR
39 (Tyr1173) and Total EGFR sandwich ELISA kits (Cell Signaling Technology®). A549 cell lysates were
40 assayed with PathScan® phospho-EGFR (Tyr1173) and Total EGFR sandwich ELISA kits (Cell Signaling
41 Technology®) whereas 8305C cell lysates were tested with the PathScan® phospho-ret (panTyr) and
42 Total Ret sandwich ELISA kits (Cell Signaling Technology®). The optical density was determined using
43 the microplate reader Multiskan Spectrum (Thermo Labsystems, Milan, Italy) set to 450 nm. All
44 experiments were repeated, independently, six times with at least 9 samples for each concentration.

2.2.5 ERK1/2 (pTpY185/187) and Akt (pThr³⁰⁸) ELISA assay

HMVEC-d (10⁵ cells/well), A549 and 8305C (5x10⁴ cells/well), were treated for 72 h with CLM3 at a concentration around the experimental IC₅₀ of cell proliferation and at a higher and lower concentrations or with vehicle alone. To measure pERK1/2 and pAkt, at the end of the experiment the cells were harvested and immediately frozen with liquid nitrogen. Cells were then lysed as described above (section 2.2.4). Each sample was then assayed for human ERK1/2 and Akt phosphorylation by the PhosphoDetect[®] ERK1/2 (pThr¹⁸⁵/pTyr¹⁸⁷) ELISA Kit and the PhosphoDetect[®] Akt (pThr³⁰⁸) ELISA Kit (Calbiochem, USA), and normalized by total protein ERK1/2 and Akt concentration measured by ERK1/2 and Akt ELISA kits, respectively. The optical density was determined using the microplate reader Multiskan Spectrum set to 450 nm. All experiments were repeated, independently, six times with at least 9 samples for each concentration.

2.2.6 Quantification of *cyclin D1* gene and protein expression in endothelial and tumor cells treated with CLM3

To investigate the modulation of gene and protein of cyclin D1 by CLM3, HMVEC-d and 8305C cells were treated for 72 h with CLM3 (100, 0.4, 0.01 nM and 100, 9.20, 0.1 μM, respectively) and vehicle alone.

To quantify cyclin D1 mRNA, RNA (1 μg) was reverse transcribed as previously described [25] and the resulting cDNA was diluted (2:3) and then amplified by QRT-PCR with the Applied Biosystems 7900HT sequence detection system. Cyclin D1, validated primer was purchased from Applied Biosystems (Assay ID Hs00277039_m1). The PCR thermal cycling conditions and optimisation of primer concentrations were followed as *per* manufacturer's instructions. Amplifications were normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the quantitation of gene expression was performed using the $\Delta\Delta C_t$ calculation, where C_t is the threshold cycle; the amount of target, normalised to the endogenous control and relative to the calibrator (vehicle-treated control cells), is given as $2^{-\Delta\Delta C_t}$. All experiments were repeated, independently, three times with at least 9 samples for each concentration.

To quantify the cyclin D1 protein, cells were directly lysed with 0.5 ml ice-cold 1X lysis buffer as described above (section 2.2.4). Lysates were collected and sonicated on ice for 10 s. The samples

1
2
3
4 were microcentrifuged for 10 min at 4°C and the supernatant was collected. Endothelial and tumor
5
6 cell lysates were assayed as *per* manufacture's instruction with the human Cyclin-D1 ELISA kit (USCN
7
8 Life Science & Technology Company, China, cat.#E0585h). The optical density was determined using
9
10 the microplate reader Multiskan Spectrum set to 450 nm. The results were expressed as cyclin D1 ng
11
12 *per* mg of total protein. All experiments were repeated, independently, six times with at least 9
13
14 samples for each concentration.
15

16 17 18 **2.3 Statistical analysis** 19

20 The results (mean \pm S.E.M.) of all the experiments were subjected to analysis of variance
21
22 between groups (ANOVA), followed by the Student-Newman-Keuls test. The level of significance was
23
24 set at $P < 0.05$.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1 CLM3 inhibits endothelial and tumour cell proliferation in a time- and concentration-dependent manner

CLM3 has shown a significant time- and concentration-dependent inhibitory activity on human cancer and endothelial cell proliferation after 24 (**figure 2A**) and 72 hours (**figure 2B**) of exposure. The microvascular endothelial cell line HMVEC-d was sensitive to low concentrations of CLM3. Indeed, the maximum effect of CLM3 was obtained in these endothelial cells (IC_{50} s 2.08 ± 0.77 nM and 0.40 ± 0.22 nM for 24h and 72h, respectively). Moreover, CLM3 showed also a time- and concentration-dependent effect on A549 cell line as outlined by the calculated IC_{50} s after 24h and 72h exposures (34.15 ± 8.9 μ M and 4.70 ± 1.80 μ M, respectively) that, however, resulted much higher than those found in endothelial cells. Interestingly, also thyroid cancer cells responded to CLM3 (**figure 2B**); furthermore, the undifferentiated thyroid cancer 8305C cell line proliferation was inhibited after 72h (IC_{50} 9.20 ± 5.06 μ M) at lower concentrations if compared to the medullary thyroid cancer TT cells (IC_{50} 26.93 ± 7.60 μ M).

3.2 Induction of apoptosis by CLM3 in endothelial and cancer cells

The extent of DNA fragmentation was dependent on the concentration of the experimental drug. In particular, the presence of chromatin fragments was detectable after 24 h and 72 h in a concentration-dependent manner for CLM3 (**figure 3**). **Figure 3A** and **3B** show a significant pro-apoptotic activity of CLM3 already after 24 h of exposure in endothelial cell and cancer cells, respectively. As shown in **figure 3C**, after 72 h of treatment with CLM3 a significant percentage of apoptotic HMVEC-d endothelial cells in the treated samples were found when compared to controls. Furthermore, the same pro-apoptotic effects of CLM3 were observed also in both cancer cell lines 8305C and A549 (**figure 3D** and **E**, respectively) even though at higher concentrations.

3.3 Synergistic effect of CLM3 and SN-38 on HMVEC-d and 8305C cell proliferation

Simultaneous and continuous exposure of HMVEC-d and 8305C cells to different concentrations of CLM3 and SN-38 for 72h showed a strong synergism ($CI < 1$ and $DRI > 1$, **figure 4** and

1
2
3
4 **table 1)**. Synergism corresponding to $CI < 1$ always yielded a favorable $DRI > 1$ for both drugs (**table 1**).
5
6 **Figure 4A** shows the CI/ Fraction affected (Fa) curve of HMVEC-d cells exposed to CLM3 and SN-38 for
7
8 72h with the simultaneous schedule of treatment. Furthermore, the simultaneous treatments of
9
10 CLM3 and SN-38 for 72h were synergistically active on undifferentiated thyroid cancer 8305C cell
11
12 proliferation, as shown by the CI/Fa curve in **figure 4B**.
13
14

15 **3.4 Inhibition of VEGFR-2, EGFR and RET phosphorylation in endothelial and cancer cells by CLM3**

16
17 After exposure to CLM3 at different concentrations, the amount of both phosphorylated forms
18
19 of VEGFR-2 and EGFR in HMVEC-d cell lysates (**figure 5A**) was significantly reduced. Moreover, the
20
21 ratio of phosphorylated/nonphosphorylated RET protein of treated cells was significantly decreased in
22
23 8305C cells (**figure 5B**).
24
25

26 **3.5 Inhibition of ERK1/2 and Akt phosphorylation in endothelial and cancer cells by CLM3**

27
28 After exposure to CLM3, the quantity of the active, phosphorylated form of ERK1/2 and Akt in
29
30 HMVEC-d cells (**figure 6A**) was significantly reduced in a concentration-dependent manner. The ratio
31
32 of phosphorylated/nonphosphorylated ERK1/2 and Akt proteins of treated cells appeared significantly
33
34 decreased also in 8305C and A549 cells, respectively (**figure 6B and C**). Interestingly, the significant
35
36 inhibition of phosphorylation of both ERK1/2 and Akt in the endothelial cell lines was obtained at
37
38 much lower concentrations if compared to cancer cells.
39
40
41

42 **3.6 CLM3 inhibits cyclin D1 gene expression and decreases cyclin D1 protein levels in endothelial and cancer cells**

43
44 In order to study the effect of CLM3 treatment to the variation of cyclin D1 expression, the
45
46 gene expression of this cell cycle protein was quantified in the endothelial HMVEC-d and 8305C cell
47
48 lines exposed to different drug concentrations. The **figure 7A and B** showed the concentration-
49
50 dependent and significant inhibition of the gene expression of cyclin D1 in HMVEC-d and 8305C cells,
51
52 respectively, by CLM3.
53
54
55

56
57 Based on these findings we measured the intracellular levels of cyclin D1 protein in treated
58
59 and untreated (vehicle only) cells. Lower cyclin D1 concentrations were found in endothelial cells
60
61 (**figure 7A**) exposed to CLM3 if compared with the ones exposed to vehicle. Of note, the same
62
63
64
65

1
2
3
4 concentration-dependent cyclin D1 decrease was obtained by CLM3 in 8305C cancer cells (**figure 7B**)
5
6 at much higher concentrations.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4. Discussion

Multiple kinases are deeply involved in tumor development and angiogenesis and their inhibition has been developed as a systemic treatment strategy for cancer [1]. Thus, the most targeted area of developing antineoplastic drugs is through the inhibition of EGFR and VEGFR signaling. This therapeutic strategy in oncology has been successful using biologics, cetuximab [26] and ramucirumab [27], as well as small molecules such as gefitinib [28], vandetanib [8], sorafenib, sunitinib [1]. As an example, the direct inhibition of VEGFR-2 tyrosine kinase activity with a small molecule (sorafenib and sunitinib) has been recently approved by the FDA for the treatment of renal cell cancer. Moreover, among newly synthesized tyrosine kinase inhibitors, a great interest have been received the pyrazolopyrimidine derivatives [29]. A considerable effort has been made over the last few years to deepen the structure-activity relationships of this class of inhibitors. Thus, a wide range of substituents, flexible or rigid, linear or cyclic, neutral or basic, has been inserted in the positions N1, N2, C3, C4 and/or C6 of the heterocyclic nucleus, in order to modulate potency and selectivity. An excellent example of lead optimization is represented by our 1-phenylethyl-pyrazolo[3,4-*d*]pyrimidine derivative, named CLM3, that has shown an *in vivo* antitumor activity in papillary dedifferentiated thyroid cancer model; indeed, CLM3 was administered in nude mice at the dose of 40 mg/kg/day for more than 20 days and it inhibited significantly the tumor growth without showing any appreciable toxicity, as demonstrated from weights of mice [30]. In this report, we identify, for the first time, the pyrazolo[3,4-*d*]pyrimidine CLM3 as a novel, multiple signal transduction inhibitor (EGFR, VEGFR-2 and RET) that has antiproliferative and proapoptotic activity on endothelial and cancer cells. Antiangiogenic tyrosine kinase inhibitors have been subdivided in three different types: i) type I kinase inhibitors that recognize the active conformation of a kinase and competitively bind to the ATP-binding site; ii) type II kinase inhibitors that recognize the inactive conformation of a kinase, occupying the hydrophobic pocket which is directly adjacent to the ATP-binding site; and finally iii) type III kinase inhibitors that covalently bind to cysteines at specific site of the kinase [1]. Due to structural analogy with type I kinase inhibitors, like vandetanib, it is reasonably plausible to include CLM3 in this class of compounds. From a preclinical point of view, the synthesis and study of this new inhibitor of tyrosine kinases had a considerable success. In fact, this new compound has shown a

1
2
3
4 significant efficacy against proliferation of endothelial and cancer cells, inhibiting the phosphorylation
5 of VEGFR-2, EGFR and RET in our cellular models. Moreover, there are recent experimental evidences
6 of autocrine activation of EGFRs and VEGFRs in papillary thyroid cancer cell lines (eg. TPC1 cells) [31]
7 that suggest a particular rationale for the use of tyrosine kinase inhibitors with dual modes of action,
8 such as vandetanib [32, 33] and sunitinib [34] for the therapeutic treatment of this kind of disease.
9 Furthermore, these compounds can also effectively act through the inhibition of tumor angiogenesis,
10 a key process of the neoplastic growth in thyroid cancers [35]. Actually, the novel inhibitor CLM3
11 displayed significant antiproliferative and pro-apoptotic effects on endothelial and cancer cells, with a
12 mechanism mediated by the inhibition of phosphorylation of ERK1/2 and Akt, respectively. In this,
13 CLM3 shows a similar behaviour to other small molecules that inhibit EGFR and VEGFR-2, such as
14 vandetanib [36, 37], or VEGFR-2 such as axitinib [38, 39], which have been shown to inhibit *in vitro*
15 both ERK1/2 and Akt phosphorylation in endothelial and cancer cells.
16
17

18
19
20
21
22
23
24
25
26
27
28 CLM3 has comparable activities also to other inhibitors of EGF-R or VEGF-R tyrosine kinases,
29 such as gefinitib, vatalanib and pazopanib, in inhibiting both the phosphorylation of the receptors in
30 cell-based assays and the *in vitro* EGF/VEGF-stimulated proliferation of endothelial and cancer cells.
31 Indeed, pazopanib potently inhibited VEGF-induced phosphorylation of VEGFR-2 in HUVEC with an
32 IC50 of ~8 nM as determined by Western blotting. In addition, in cellular assays pazopanib inhibited
33 proliferation of VEGF-driven HUVEC with an IC50 of 21 nM, with a 35-fold selectivity over bFGF-
34 induced HUVEC proliferation. The inhibition of VEGF-induced HUVEC proliferation was greater than
35 1400-fold more selective than that observed for inhibition of proliferation of a variety of tumor cells
36 and greater than 48-fold for fibroblasts [40]. In cell-based assays, vatalanib inhibits VEGF-induced
37 VEGFR-2 phosphorylation with IC50 values of 17 nM (endothelial cells) and 34 nM (CHO cells
38 transfected with VEGFR-2). The compound inhibited HUVEC proliferation, migration, and survival with
39 IC50 values of 7.1, 58, and <10 nM, respectively, but did not inhibit the proliferation of A431 or
40 DU145 cells even at concentrations of up to 1 μ M [41]. The antitumor activity of vatalanib has been
41 also investigated *in vitro* on anaplastic thyroid carcinoma (ATC) cell lines and it has been found that
42 vatalanib did not affect the proliferation of these cell lines [42].
43
44
45
46
47
48
49
50
51
52
53
54
55

56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Gefitinib was the first small molecule inhibitor of EGFR to enter clinical trials. In preclinical studies, gefitinib completely blocked EGF-stimulated EGFR phosphorylation at 0.16 μ M in Du145 (prostate) and A549 (lung) cells, whereas complete inhibition was achieved at 0.8 μ M in KB (oral

1
2
3
4 squamous) and HT29 (colon) tumor cells [43]. Moreover, gefitinib was a potent and selective inhibitor
5 of EGF-stimulated KB tumor cell growth *in vitro*. Selectivity was demonstrated by the >100-fold
6 difference in IC₅₀ for cells grown in the presence (IC₅₀, 0.054 μM) or absence (IC₅₀, 8.8 μM) of EGF.
7
8 Similarly, gefitinib selectively inhibited EGF-stimulated growth of HUVECs (IC₅₀, 0.03-0.1 μM)
9 compared with FGF- or VEGF-stimulated growth (IC₅₀, 1-3 μM) [43].

10
11
12
13
14 Regulated progression through the cell cycle requires sequential expression of a family of
15 proteins called cyclins. Induction of the proto-oncogene cyclin D1, and its binding to CDK4 or CDK6, is
16 a rate limiting event during cell-cycle progression through G1 phase [44]. When cancer cells are
17 cultured as multicellular aggregates, cyclin D1 is induced through a serum-dependent EGFR activating
18 pathway, triggering cell proliferation. The expression of cyclin D1 required both EGFR-mediated ERK
19 and Akt activation [45]. Blocking EGFR function inhibits the expression of cyclin D1 and proliferation
20 [46]. Indeed, CLM3, after inhibiting EGFR and VEGFR-2 phosphorylation and consequently ERK and Akt
21 activities, determines the suppression of cyclin D1 both at gene expression and protein levels. It has
22 been previously demonstrated that in non-transformed cells, the cyclin D1 gene senses the mitogenic
23 potential of the microenvironment because its induction requires coordinated signaling from the
24 extracellular matrix and soluble growth factors [44]. Activators of cyclin D1 gene transcription are
25 mitogenic growth factors, and, it has been described that also nuclear EGFR is able to bind the cyclin
26 D1 promoter, promoting the gene transcription [47]. Interestingly, also vandetanib inhibited cell
27 proliferation in a dose-dependent manner, by blocking cell progression at the G0-G1 stage, through
28 the downregulation of expression of cyclin D1 and cyclin E [37].

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 The association of CLM3 with SN-38, the active metabolite of irinotecan, showed a marked
44 synergistic effect on endothelial and cancer cells, placing our compound on the same level as those
45 currently being tested for combination chemotherapy regimens, such as vandetanib [48], pazopanib
46 [49] and axitinib [39]. In order to improve the antineoplastic activity of CLM3, we presently
47 investigated the effects of CLM3 in combination with SN-38 in EGFR and VEGFR-2 expressing human
48 endothelial cell line HMVEC-d and in EGFR and RET expressing human thyroid cancer cell 8305C [50].
49 CLM3 synergistically decreased cell proliferation when used in combination with SN-38, suggesting
50 that incorporating chemotherapy (SN-38) with an anti-EGFR, VEGFR and RET strategy (CLM3) may be
51 more effective in treating patients with thyroid cancer than either approach alone [30]. Furthermore,
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 our *in vitro* data are similar to the ones obtained with other pyrazolo[3,4-*d*]pyrimidines alone, like PP1
5 and PP2 [51], Si34 and Si35 [52, 53].
6
7

8 In general, the clinical development of schedules including the combination of camptothecins
9 (i.e. irinotecan and topotecan) and tyrosine kinase inhibitors (TKIs; i.e. pazopanib, axitinib and
10 sunitinib) appears not only possible but very promising based on the involved pharmacodynamic
11 mechanisms of their synergism [39, 49]. Even though it is still premature to predict the clinical
12 perspective for the new compound CLM3, the possible immediate clinical significance of our results is
13 the development of a rational strategy for irinotecan/TKIs combination. Indeed, our study confirms
14 and strongly supports the possible winning strategy of combining schedules that includes, in
15 particular, camptothecins and VEGFRs/EGFRs TKIs. Moreover, based on our experimental data, we
16 could suggest in future clinical trials that, in simultaneous combination of irinotecan and a VEGFR
17 and/or EGFR TKI, the dose levels can be reduced with respect to their maximum tolerated total dose
18 or optimal biological dose and that a possible new pharmacodynamic marker can be used to monitor
19 the therapy such as the cyclin D1 protein concentration.
20
21
22
23
24
25
26
27
28
29
30

31 In conclusion, the pyrazolopyrimidine derivative CLM3 demonstrated a highly significant and
32 promising antiproliferative and proapoptotic activity, alone and in combination with SN-38, for
33 activated endothelial and cancer cells. These effects are mainly due to its inhibition of
34 phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signalling pathways,
35 including the downregulation of cyclin D1.
36
37
38
39
40
41
42

43 **Acknowledgements**

44
45 The authors thank Prof. Franco Bocci. The present study has been supported by a grant of
46 MIUR (Italian Ministry for the University and Research) PRIN (Progetti di Interesse Nazionale) 2007 to
47 G.B. There was no role of MIUR in study design; in the collection, analysis and interpretation of data;
48 in the writing of the report; and in the decision to submit the paper for publication.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legends

Figure 1. Chemical structure of the (R)-1-phenethyl-N-(1-phenylethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine CLM3.

Figure 2. Effect of CLM3 on *in vitro* cell proliferation after 24 h (A) and 72 h (B) exposures. The antiproliferative effects of the drugs were studied using continuous exposures on HMVEC-d, A549, TT and 8305C cell lines. *Symbols and bars*, mean values \pm SE, respectively. * $P < 0.05$ vs. vehicle-treated controls. IC₅₀, the concentration of drug that reduced cell proliferation by 50%.

Figure 3. Pro-apoptotic effects of CLM3 on proliferating HMVEC-d (A) and A549 (B) cells treated for 24 h. The apoptotic effects were also tested after 72 h on HMVEC-d (C), 8305C (D) and A549 (E) cells. *Columns and bars*, mean values \pm SE, respectively. * $P < 0.05$ or $P < 0.01$ vs. vehicle-treated controls. *Control-* stands for the negative control of the ELISA kit.

Figure 4. Combination Index/Fraction affected curves of HMVEC-d (A), and 8305C (B) cell proliferation inhibition by simultaneous combination of CLM3 and SN-38, the active metabolite of irinotecan. The symbols represents the combination index values (synergism $CI < 1$) *per* the fraction of cells affected by the combination.

Figure 5. Inhibition of VEGFR-2 and EGFR phosphorylation by CLM3 in HMVEC-d cells after 72 h of treatment (A). pVEGFR-2 and pEGFR concentrations were measured by ELISA kits and they were normalized to total VEGFR-2 and EGFR protein concentration, respectively. Inhibition of RET phosphorylation by CLM3 in 8305C cells after 72 h of treatment (B). pRET concentrations were measured by an ELISA kit and they were normalized to total RET protein concentration. *Columns and bars*, mean values \pm SE, respectively. * $P < 0.05$ vs. vehicle-treated controls.

Figure 6. Inhibition of Akt (pThr³⁰⁸) and ERK1/2 (pThr¹⁸⁵/pTyr¹⁸⁷) phosphorylation by CLM3 in HMVEC-d (A), 8305C (B) and A549 (C) cells after 72 h of treatment. pAkt and pERK1/2 concentrations were

1
2
3
4 measured by ELISA kits and they were normalized to total Akt and ERK1/2 protein concentration,
5 respectively. *Columns* and *bars*, mean values \pm SE, respectively. * P < 0.05 vs. vehicle-treated controls.
6
7
8
9

10 **Figure 7.** *Cyclin D1* gene expression and cyclin D1 protein concentrations in HMVEC-d (A) and 8305C
11 (B) cells exposed to CLM3 or with vehicle alone for 72 h. *Columns* and *bars*, mean values \pm SE,
12 respectively. * P < 0.05 vs. vehicle-treated controls.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- [1] Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? *Angiogenesis* 2010;13:1-14.
- [2] Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. *Anticancer Agents Med Chem* 2009;9:66-76.
- [3] Ferrara N. Vascular endothelial growth factor. *Arterioscler Thromb Vasc Biol* 2009;29:789-91.
- [4] Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. *Nat Rev Clin Oncol* 2009;6:569-79.
- [5] Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. *Biochem Pharmacol* 2010;80:613-23.
- [6] Ball DW. Medullary thyroid cancer: monitoring and therapy. *Endocrinol Metab Clin North Am* 2007;36:823-37, viii.
- [7] Hoekman K, Van Crujisen H, Giaccone G. The EGF (R) and VEGF (R) pathways as combined targets for anti-angiogenesis trials in cancer therapy. In: Marmé D, Fusenig N, editors. *Tumor Angiogenesis Basic Mechanisms and Cancer Therapy*. Berlin: Springer, 2007 p. 707-15.
- [8] Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. *Oncologist* 2009;14:378-90.
- [9] Okamoto K, Neureiter D, Alinger B, Meissnitzer M, Sass G, Schmitz V, et al. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. *Int J Oncol* 2008;33:733-42.
- [10] Lorient Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC, et al. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. *Br J Cancer* 2010;103:347-53.

- 1
2
3
4 [11] Pennell NA, Lynch TJ, Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the
5 treatment of NSCLC. *Oncologist* 2009;14:399-411.
6
7
8 [12] Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with
9 locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Endocrinol Metab*
10 2010;95:2664-71.
11
12
13 [13] Wells SA, Jr., Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the
14 treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
15 *J Clin Oncol* 2010;28:767-72.
16
17
18 [14] Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus
19 docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell
20 lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. *Lancet Oncol* 2010;11:619-26.
21
22
23 [15] Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? *Science*
24 2006;312:1171-5.
25
26
27 [16] Rossi A, Schenone S, Angelucci A, Cozzi M, Caracciolo V, Pentimalli F, et al. New pyrazolo-[3,4-
28 d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth
29 reduction of human medulloblastoma cells. *FASEB J* 2010;24:2881-92.
30
31
32 [17] Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, Ranise A, et al. Pyrazolo[3,4-d]pyrimidines
33 endowed with antiproliferative activity on ductal infiltrating carcinoma cells. *J Med Chem*
34 2004;47:1595-8.
35
36
37 [18] Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, et al. C6-unsubstituted
38 pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate
39 resistant chronic myeloid leukemia cell lines. *ChemMedChem* 2009;4:118-26.
40
41
42 [19] Carraro F, Naldini A, Pucci A, Locatelli GA, Maga G, Schenone S, et al. Pyrazolo[3,4-
43 d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC
44 cells in culture via inhibition of c-Src phosphorylation. *J Med Chem* 2006;49:1549-61.
45
46
47 [20] Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, et al. New pyrazolo[3,4-
48 d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src
49 phosphorylation. *Bioorg Med Chem Lett* 2004;14:2511-7.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [21] Navarra M, Celano M, Maiuolo J, Schenone S, Botta M, Angelucci A, et al. Antiproliferative and
5 pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.
6 BMC Cancer 2010;10:602.
7
8
9
10 [22] Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, et al. Use of a pharmacophore model for the
11 design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med
12 Chem 1997;40:3601-16.
13
14
15 [23] Bocci G, Da Settimo F, Del Tacca M, Fioravanti A, La Motta C, Martini C, et al. Preparation of
16 2*H*-pyrazolo[3,4-*d*]pyrimidine derivatives as inhibitors of protein tyrosine kinase receptor. Ital.
17 Appl. IT2007RM0480, 2007.
18
19
20 [24] Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism
21 and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
22
23
24 [25] Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, et al. Fluvastatin
25 synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer
26 MIAPaCa-2 cells. Br J Cancer 2005;93:319-30.
27
28
29 [26] Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
30 Drugs 2010;70:1987-2010.
31
32
33 [27] Spratlin J. Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial
34 Growth Factor Receptor-2. Curr Oncol Rep 2011;13(2):97-102.
35
36
37 [28] Gupta A, Raina V. Gefitinib. J Cancer Res Ther 2010;6:249-54.
38
39
40 [29] Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, et al. Determination of
41 permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation
42 with biological data. Eur J Med Chem 2009;44:3712-7.
43
44
45 [30] Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, et al. Novel
46 Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro
47 and in Vivo in Papillary Dedifferentiated Thyroid Cancer. J Clin Endocrinol Metab
48 2011;96:E288-E96.
49
50
51 [31] Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer LC, et al. Differential
52 effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular
53 endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine
54 2007;31:105-13.
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [32] Carlomagno F, Guida T, Anaganti S, Provitera L, Kjaer S, McDonald NQ, et al. Identification of
5 tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. *Endocr Relat*
6 *Cancer* 2009;16:233-41.
7
8
9
10 [33] Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally
11 available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
12 *Cancer Res* 2002;62:7284-90.
13
14
15 [34] Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget
16 tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic
17 RET/papillary thyroid cancer kinases. *J Clin Endocrinol Metab* 2006;91:4070-6.
18
19
20 [35] Mitchell JC, Parangi S. Angiogenesis in benign and malignant thyroid disease. *Thyroid*
21 2005;15:494-510.
22
23
24 [36] Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474 enhances paclitaxel
25 antiproliferative and apoptotic effects in breast carcinoma cells. *J Cell Physiol* 2011;226:375-
26 84.
27
28
29 [37] Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase
30 inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in
31 breast cancer cells. *Cancer Biol Ther* 2010;9:592-603.
32
33
34 [38] Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical
35 antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and
36 selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. *Clin*
37 *Cancer Res* 2008;14:7272-83.
38
39
40 [39] Canu B, Fioravanti A, Orlandi P, Di Desidero T, Ali G, Fontanini G, et al. Irinotecan
41 synergistically enhances the antiproliferative and pro-apoptotic effects of axitinib *in vitro* and
42 improves its anticancer activity *in vivo*. *Neoplasia* 2011;13:217-29.
43
44
45 [40] Harris P, Stafford J. Discovery of pazopanib: a pan vascular endothelial growth factor kinase
46 inhibitor. In: Li R, Stafford J, editors. *Kinase Inhibitor Drugs*. Hoboken, New Jersey: John Wiley
47 & Sons, Inc., 2009.
48
49
50 [41] Matthews D, Gerritsen M. *Angiokinase Inhibitors. Targeting Protein Kinases for Cancer*
51 *Therapy*. Hoboken, New Jersey: John Wiley & Sons, Inc., 2010.
52
53
54
55
56
57
58
59
60
61
62
63
64
65


- 1
2
3
4 [42] Kim S, Yazici YD, Barber SE, Jasser SA, Mandal M, Bekele BN, et al. Growth inhibition of
5 orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and
6 CPT-11. *Head Neck* 2006;28:389-99.
7
8
9 [43] Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an
10 orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
11 *Cancer Res* 2002;62:5749-54.
12
13 [44] Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. *J Cell Sci*
14 2008;121:3853-7.
15
16 [45] Humtsoe JO, Kramer RH. Differential epidermal growth factor receptor signaling regulates
17 anchorage-independent growth by modulation of the PI3K/AKT pathway. *Oncogene*
18 2010;29:1214-26.
19
20 [46] Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates
21 cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. *Cancer Res*
22 2001;61:6583-91.
23
24 [47] Tao Y, Song X, Deng X, Xie D, Lee LM, Liu Y, et al. Nuclear accumulation of epidermal growth
25 factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent
26 membrane protein 1. *Exp Cell Res* 2005;303:240-51.
27
28 [48] Wachsberger P, Burd R, Ryan A, Daskalakis C, Dicker AP. Combination of vandetanib,
29 radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. *Int J*
30 *Radiat Oncol Biol Phys* 2009;75:854-61.
31
32 [49] Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of
33 metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for
34 the treatment of ovarian cancer. *Mol Cancer Ther* 2010;9:996-1006.
35
36 [50] Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O. Expression of KIT,
37 EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication
38 for a new therapeutic approach. *Pathol Int* 2005;55:757-65.
39
40 [51] Carlomagno F, Santoro M. Identification of RET kinase inhibitors as potential new treatment
41 for sporadic and inherited thyroid cancer. *J Chemother* 2004;16 Suppl 4:49-51.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- [52] Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, et al. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. *J Endocrinol Invest* 2007;30:RC31-4.
- [53] Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, et al. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. *Endocr Relat Cancer* 2008;15:499-510.

Table 1. Dose-reduction index (DRI) values for the drug combinations at 25%, 50% and 75% level of inhibition of HMVEC-d and 8305C cell proliferation.

<i>Cells</i>	DRI values					
	25%		50%		75%	
	<i>CLM3</i>	<i>SN-38</i>	<i>CLM3</i>	<i>SN-38</i>	<i>CLM3</i>	<i>SN-38</i>
HMVEC-d	1.116	94.867	5.874	23.626	30.911	5.884
8305C	2.550	27.837	2.494	146.493	2.440	770.927



CLM3










Figure 2

A**B****C****D****E****Figure 3**





Figure 4





Figure 5




Figure 6





Figure 7

